To analyze the application of tirofiban after intravenous thrombolysis with Tenecteplase in elderly patients with acute ischemic stroke (AIS).
The clinical data of 168 elderly patients with moderate vascular occlusion AIS who received intravenous thrombolysis with Tenecteplase in Handan First Hospital from January 2023 to December 2024 were collected. Among them, 82 patients (control group) did not receive antiplatelet therapy within 24 h after intravenous thrombolysis, and 86 (tirofiban group) were given tirofiban intravenous infusion for 24 h after excluding those with bleeding 2 h after intravenous thrombolysis. Cranial imaging examination was performed at 3 d after thrombolysis to assess vascular recanalization. Neurological deficits [national institutes of health stroke scale (NIHSS)] and incidence rate of early neurological deterioration (END) were recorded in both groups before thrombolysis and at 1, 7 and 14 d after thrombolysis. The differences in laboratory indexes [activated partial thromboplastin time (APTT), fibrinogen (FIB), hematocrit (HCT), platelet count (PLT)] before thrombolysis and at 14 d after thrombolysis were compared between the two groups. The occurrence of cerebral hemorrhage transformation (HT) and systemic bleeding within 3 d after thrombolysis were recorded. The modified Rankin scale (mRS) was used to assess the prognosis in the two groups at 90 d after thrombolysis. SPSS statistics 24.0 was used for statistical analysis. Data comparison between two groups was perfomed using t test, analysis of Variance, χ2 test or Fisher′s exact probability test depending on data type.
Using propensity score matching to eliminate unbalanced variables, 78 well-matched patients were obtained, i.e., 78 patients each in the tirofiban group and the control group. The degree of vascular recanalization and the recanalization rate in the tirofiban group were higher than those in the control group [75.64% (59/78) vs 58.97% (46/78); P< 0.05]. The NIHSS scores after thrombolysis decreased compared with before thrombolysis in both groups (P< 0.05), the NIHSS scores at 14 d after thrombolysis were lower than those at 1 and 7 d after thrombolysis (P< 0.05), and the NIHSS scores at 7 d after thrombolysis was lower than those at 1 d after thrombolysis (P< 0.05). The NIHSS scores at 1, 7 and 14 d after thrombolysis and the incidence rate of END [2.56% (2/78) vs 11.54% (9/78), P< 0.05] in the tirofiban group were lower than those in the control group. There were no statistical differences in APTT, FIB, HCT and PLT within groups before and after thrombolysis and between the two groups (all P> 0.05). The differences in incidence rates of HT and the total incidence rates of systemic bleeding events between the tirofiban group and the control group were not statistically significant (P> 0.05). At 90 d after thrombolysis, the proportion of patients with mRS ≤ 2 points in the tirofiban group was higher than that in the control group [92.31% (72/78) vs 80.77% (63/78)], and the difference was statistically significant (P< 0.05).
Early combination of tirofiban after intravenous thrombolysis with Tenecteplase demonstrateds good efficacy and safety in the treatment of elderly AIS patients with moderate vascular occlusion, showing certain advantages in promoting vascular recanalization, reducing END, and improving short-term prognosis.
京公网安备11010802044758号